Corticosterone and dexamethasone potentiate cytotoxicity associated with oxygen-glucose deprivation in organotypic cerebellar slice cultures.
Many patients display elevated levels of serum cortisol following acute ischemic stroke. Given that glucocorticoids may potentiate some forms of insult, these studies examined the effects of corticosterone or dexamethasone exposure on cytotoxicity following oxygen-glucose deprivation in the cerebellum, a brain region susceptible to stroke. In organotypic cerebellar slice cultures prepared from neonatal rat pups, 90-min of oxygen-glucose deprivation at 15 days in vitro resulted in significant cytotoxicity at 24-, 48-, and 72-h post-oxygen-glucose deprivation, as measured by uptake of propidium iodide. Exposure of cultures following oxygen-glucose deprivation to the antioxidant trolox (500 microM), but not to the glucocorticoid receptor antagonist RU486 (10 microM), completely blocked oxygen-glucose deprivation-induced cytotoxicity. Corticosterone (1 microM) or dexamethasone (10 microM) exposure alone did not significantly increase propidium iodide uptake above levels observed in control cultures. However, corticosterone or dexamethasone exposure after oxygen-glucose deprivation potentiated oxygen-glucose deprivation-mediated propidium iodide uptake at each time point. Trolox, as well as RU486, co-exposure of cultures to corticosterone or dexamethasone after oxygen-glucose deprivation abolished all cytotoxicity. In conclusion, these data demonstrated that glucocorticoid exposure modulated oxygen-glucose deprivation-mediated propidium iodide uptake, which likely involved glucocorticoid receptor activation and pro-oxidant effects.
Mulholland
P J
PJ
Department of Psychology, University of Kentucky, 115 Kastle Hall, Lexington, KY 40506-0044, USA. mulholl@musc.edu
Stepanyan
T D
TD
Self
R L
RL
Hensley
A K
AK
Harris
B R
BR
Kowalski
A
A
Littleton
J M
JM
Prendergast
M A
MA
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D016923:Cell Death / Q000187:drug effects; D002531:Cerebellum / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology*; D002839:Chromans / Q000494:pharmacology; D003345:Corticosterone / Q000494:pharmacology*; D003907:Dexamethasone / Q000494:pharmacology*; D004357:Drug Synergism; D005260:Female; D005947:Glucose / Q000172:deficiency*; D000860:Hypoxia / Q000503:physiopathology*; D066298:In Vitro Techniques; D008297:Male; D015735:Mifepristone / Q000494:pharmacology; D011419:Propidium / Q000493:pharmacokinetics; D051381:Rats; D017207:Rats, Sprague-Dawley
D000975:Antioxidants; D002839:Chromans; D015735:Mifepristone; D011419:Propidium; D003907:Dexamethasone; D005947:Glucose; C010643:6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; D003345:Corticosterone